摘要
AIM:To investigate the prophylactic and therapeutic efficacy of intraperitoneal IL-2 innunotherapy following intraperitoneal thermochemotheray int the metastasis and recurrence of gastric and colorectal cancer after operation.
AIM:To investigate the prophylactic and therapeutic efficacy of intraperitoneal IL-2 immunotherapy following intraperitoneal thermochemotherapy in the metastasis and recurrence of gastric and colorectal cancer after operation. METHODS:Forty-two gastric cancer patients at T_3Ⅱ-T_4 Ⅲ_B stages and 96 patients with colorectal cancer at B to D stages admitted from January 1996 to October 1998 were randomly divided into control group(group Ⅰ,65 cases)receiving intraperitoneal thermochemotherapy,and group Ⅱ(73 cases)receiving both intraperitoneal thermochemotherapy and intraperitoneal IL-2 immunotherapy.Distilled water at 43-45℃ containing 5-Fu 0.5 g/L and MMC 8 mg/L was perfused into peritoneal cavity before closure at the end of operation for 1 h,and from the third day,IL-2 10 million IU in 500 ml 0.9 % sodium chloride was intraperitoneally administrated daily for 10 times.One month after operation, all the patients underwent regular intravenous chemotherapy. Before and after the IL-2 immunotherapy,some Th1 type cytokines in the peripheral blood of the patients in the two groups were detected by ELISA,and the intraperitoneal recurrence and liver metastasis rates and the 3-year survival rate were statistically evaluated after intensive follow-up. RESULTS:IL-2 intraperitoneal immunotherapy significantly elevated the level of some Thl type cytokines(P<0.01 compared with that of control group),and the 3-year survival rate of group Ⅱ was 18.1% higher and the rates of intraperitoneal recurrence and liver metastasis were 16.9 % and 6.0 % lower than those of group I significantly (P<0.05-0.01). CONCLUSION:The combination of intraperitoneal IL-2 immunotherapy and thermochemotherapy could promote Thl immune paradigm and enforce anti-tumor activity of bodies,which plays a positive role in preventing gastric and colorectal cancer from intraperitoneal recurrence and development.
